![]() It said it expects to close the transaction in the first quarter of 2014. Skadden, Arps, Slate, Meagher & Flom Llp and Wikborg, Rein & Co. ![]() Goldman Sachs International provided financial advice to Algeta, DNB Markets provided a formal statement under Norwegian securities law, which included a fairness opinion, and Centerview Partners provided an additional fairness opinion for Algeta. Health economics and Radium-223 (Xofigo) in the Metastatic. Owners of 14% of the stock, including members of the board, senior executives and the biggest shareholder, HealthCap IV, have agreed to accept the offer, Algeta said. Cancer drug costs for a month of treatment at initial Food and Drug. Total costs and QALYs were 65 067 and 1.12 QALYs for radium-223 and 55 437 and 0.77 QALYs. Use effective contraceptive methods during & up to 6 mth after treatment. will give you a lower total cost compared to filling the same prescription multiple times. Potential risk of impaired human fertility. Save more on your prescription medication with Xofigo coupons. Potential effects on spermatogenesis associated w/ radiation. The offer is contingent on acceptance by 90% of the shares, the companies said. Not recommended for use in combination w/ abiraterone acetate + prednisone/prednisolone, or other chemotherapy. ![]() The purchase price is 37% above Algeta’s closing level on 25 November, the day before the company said it was in talks with Bayer.Īlgeta’s board recommended the offer unanimously, the Oslo- based company said in a separate statement. “We are absolutely convinced of the potential of this drug and the underlying technology to provide patients with innovative treatment options," Bayer’s chief executive officer Marijn Dekkers said in the statement.īayer rose 0.3% to €98.58 at 9:04am in Frankfurt trading.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |